Glucagon-Like Peptide 1 Receptor Agonists and Risk of Thyroid Cancer: An International Multisite Cohort Study
Authors:
Top Cited Papers
- 16 January 2025
- journal article
- research article
- Published by SAGE Publications in Thyroid®
- Vol. 35 (1) , 69-78
Abstract
Introduction: Concerns have been raised that glucagon-like peptide 1 receptor agonists (GLP1-RAs) may increase the risk of thyroid cancer, but evidence remains conflicting. We therefore investigated if GLP1-RA use, compared with use of dipeptidyl peptidase-4 inhibitors (DPP-4is), was associated with thyroid cancer risk in patients with type 2 diabetes. Methods: This multisite cohort study with subsequent meta-analysis included six population-based databases from Canada (Ontario), Denmark, Norway, South Korea, Sweden, and Taiwan. Study populations comprised patients with type 2 diabetes between 2007 and 2023. Cox regression models estimated hazard ratios (HR) and 95% confidence intervals (CIs) for thyroid cancer among GLP1-RA users compared with DPP-4is. Models were weighted using standardized mortality ratio weights generated from time-specific propensity scores. Site-specific HRs were pooled using a fixed-effects model. Results: We identified 98,147 users of GLP1-RA and 2,488,303 users of DPP-4i, with the median follow-up among users of GLP1-RA ranging from 1.8 to 3.0 years. Overall, use of GLP1-RA relative to use of DPP-4i was not associated with an increased risk of thyroid cancer (pooled weighted HR 0.81, CI 0.59–1.12). Similarly, we observed no increased risk in thyroid cancer with increasing cumulative dose of GLP1-RA among GLP1-RA ever-users. Subgroup analysis of types of thyroid cancer was not possible. Results remained consistent across a range of supplementary analyses. Discussion: In this large multisite study, utilizing data from six population-based databases, we found no evidence that GLP1-RA use is associated with an increased risk of thyroid cancer with follow-up ranging from 1.8 to 3.0 years, providing some reassurance to patients and clinicians about the short-term safety of these drugs. Nevertheless, evidence was insufficient to rule out excess risk with long-term use, due to the short follow-up.Keywords
This publication has 40 references indexed in Scilit:
- Semaglutide and cancer: A systematic review and meta-analysisDiabetes & Metabolic Syndrome: Clinical Research & Reviews, 2023
- The application of lag times in cancer pharmacoepidemiology: a narrative reviewAnnals of Epidemiology, 2023
- HARmonized Protocol Template to Enhance Reproducibility of hypothesis evaluating real‐world evidence studies on treatment effects: A good practices report of a joint ISPE/ISPOR task forcePharmacoepidemiology and Drug Safety, 2022
- Core concepts in pharmacoepidemiology: Confounding by indication and the role of active comparatorsPharmacoepidemiology and Drug Safety, 2022
- Analysing data and undertaking meta‐analyses2019
- Calendar time‐specific propensity scores and comparative effectiveness research for stage III colon cancer chemotherapyPharmacoepidemiology and Drug Safety, 2013
- A meta-analysis of serious adverse events reported with exenatide and liraglutide: Acute pancreatitis and cancerDiabetes Research and Clinical Practice, 2012
- Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity‐score matched samplesStatistics in Medicine, 2009
- The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesThe Lancet, 2006
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002